Raymond James Financial Services Advisors Inc. lowered its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) by 2.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,935 shares of the biotechnology company’s stock after selling 1,259 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in REGENXBIO were worth $1,452,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. SummerHaven Investment Management LLC acquired a new position in shares of REGENXBIO in the 3rd quarter valued at $691,000. Louisiana State Employees Retirement System acquired a new position in shares of REGENXBIO in the third quarter valued at about $476,000. Goldman Sachs Group Inc. increased its holdings in shares of REGENXBIO by 320.0% in the second quarter. Goldman Sachs Group Inc. now owns 500,125 shares of the biotechnology company’s stock valued at $12,353,000 after purchasing an additional 381,047 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of REGENXBIO by 21.7% in the second quarter. Thrivent Financial for Lutherans now owns 37,293 shares of the biotechnology company’s stock worth $921,000 after purchasing an additional 6,654 shares during the last quarter. Finally, Prudential Financial Inc. lifted its holdings in shares of REGENXBIO by 128.9% during the second quarter. Prudential Financial Inc. now owns 90,352 shares of the biotechnology company’s stock worth $2,232,000 after purchasing an additional 50,885 shares during the period. 80.21% of the stock is owned by hedge funds and other institutional investors.
REGENXBIO Stock Down 1.2 %
NASDAQ:RGNX opened at $22.67 on Friday. REGENXBIO Inc. has a 52 week low of $18.69 and a 52 week high of $35.73. The stock’s 50-day moving average price is $22.75 and its 200-day moving average price is $25.84. The stock has a market capitalization of $981.47 million, a PE ratio of 14.63 and a beta of 0.99.
Analyst Ratings Changes
A number of equities analysts have issued reports on RGNX shares. Morgan Stanley reduced their price target on shares of REGENXBIO from $52.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 21st. StockNews.com assumed coverage on shares of REGENXBIO in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Chardan Capital reduced their price objective on REGENXBIO from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Friday, November 4th. Royal Bank of Canada decreased their price objective on REGENXBIO from $47.00 to $29.00 in a report on Tuesday, October 4th. Finally, Wedbush dropped their target price on REGENXBIO from $32.00 to $28.00 and set a “neutral” rating on the stock in a report on Tuesday, October 4th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.43.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
- Get a free copy of the StockNews.com research report on REGENXBIO (RGNX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.